Dacmed 200mg Injection

Dacmed 200mg Injection belongs to the category of anticancer medicines. It is used in the treatment of skin cancer that has spread to other body parts, and Hodgkin's disease (cancer that affects the lymphatic system). The active ingredient of the Dacmed 200mg is Dacarbazine, which belongs to the drug class of alkylating agents.

It is administered as an injection by an experienced nurse or medical professional. Dacmed Injection works by killing the cancer cells, thereby reducing the size of the tumor. In this way, it prevents cancer cells from spreading to other parts of the body. The doctor decides the required dosage and duration of the medicine.

• Skin cancer
• Hodgkin's lymphoma

The human body shows undesired symptoms after taking Dacmed 200mg Injection. Usually, they disappear with time as the body adjusts to the medicine. These side effects don't need special medical attention. It is advised to consult your doctor if these symptoms become unmanageable.

Some of the common side effects are mentioned below:

• Low levels of RBC, WBC and platelets in blood.
• Loss of appetite
• Nausea, vomiting
• Hair loss
• Skin reactions

Serious

• Sore throat or high temperature indicating infection
• Unusual bleeding or bruising
• Severe vomiting or diarrhea
• Extreme tiredness
• Severe allergic reaction, characterized by swelling of hands, feet, ankles, face, lips, mouth or throat; rashes or giddiness.
• Headache, vision problems, fits, confusion, lethargy or numbness of face
• Severe liver problems

• Dacmed 200mg Injection is a prescription-based anticancer drug. It is advised to take this injection after consulting your healthcare expert.
• This medicine should be given intravenously by an experienced nurse or doctor. Please do not self-administer.
  
  

• The active ingredient of the Dacmed 200mg Injection is Dacarbazine, which belongs to the drug class of alkylating agents that works by alkylation. It inhibits DNA synthesis, which disturbs the normal functioning of DNA.
• This process arrests the growth and proliferation of cancer cells, eventually leading to their death. In this way, it slows the progression of cancer.
  

• Hafeez, A., & Kazmi, I. (2017). Dacarbazine nanoparticle topical delivery system for the treatment of melanoma. Scientific reports, 7(1), 16517. https://www.nature.com/articles/s41598-017-16878-1
• Ugurel, S., Paschen, A., & Becker, J. C. (2013). Dacarbazine in melanoma: from a chemotherapeutic drug to an immunomodulating agent. Journal of Investigative Dermatology, 133(2), 289-292. https://pubmed.ncbi.nlm.nih.gov/23318786/
• Cocconi, G., Bella, M., Calabresi, F., Tonato, M., Canaletti, R., Boni, C., ... & Bacchi, M. (1992). Treatment of metastatic malignant melanoma with dacarbazine plus tamoxifen. New England Journal of Medicine, 327(8), 516-523. https://pubmed.ncbi.nlm.nih.gov/1635566/
• Eggermont, A. M., & Kirkwood, J. M. (2004). Re-evaluating the role of dacarbazine in metastatic melanoma: what have we learned in 30 years?. European journal of cancer, 40(12), 1825-1836. https://pubmed.ncbi.nlm.nih.gov/15288283/
• Reid, J. M., Kuffel, M. J., Miller, J. K., Rios, R., & Ames, M. M. (1999). Metabolic activation of dacarbazine by human cytochromes P450: the role of CYP1A1, CYP1A2, and CYP2E1. Clinical Cancer Research, 5(8), 2192-2197.    https://pubmed.ncbi.nlm.nih.gov/10473105/